Evidence map›Paper›PMID 36450416›Full record

ArticleBMJ case reports2022

Renal injury in scleromyxoedema due to monoclonal gammopathy associated C3 glomerulonephritis.

Stephanie Kao, Sonia D Silinsky Krupnikova, Maha AlMackenzie, Gelareh Atefi

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Stephanie KaoDepartment of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA skao@mfa.gwu.edu.
Sonia D Silinsky KrupnikovaArthritis and Rheumatism Associates, PC, Wheaton, Maryland, USA.
Maha AlMackenzieDivision of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia.
Gelareh AtefiImmunology, AstraZeneca, Wilmington, Delaware, USA.
Arthritis and Rheumatism Associates · USAstraZeneca (United States) · USGeorge Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scleromyxoedema is a rare mucinosis that primarily affects the skin. It is associated with monoclonal gammopathy and has many extracutaneous manifestations, however, renal involvement is rare. We report the case of a woman with monoclonal gammopathy and scleromyxoedema presenting with progressive exertional dyspnoea and acute renal failure. Workup of her renal failure revealed monoclonal gammopathy associated C3 glomerulonephritis. She was treated with intravenous steroids and discharged with plans to pursue annual monoclonal gammopathy laboratory monitoring. Given the rarity of renal scleromyxoedema, careful investigation of extracutaneous manifestations and comorbidities is critical to discern the primary pathological process in patients with scleromyxoedema who develop renal insufficiency.

Indexed as

GlomerulonephritisMonoclonal Gammopathy of Undetermined SignificanceRenal InsufficiencyScleromyxedemaDyspneaFemaleHumansKidneyAcute renal failureRheumatology

Identifiers

PMID36450416
PMCPMC9716891
OpenAlexW4310580597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.